SCHEMBL4897263

SCHEMBL4897263

COc1cc(CC(=O)Cl)c(F)c(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.43
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
LMNA P02545 2/20 0.37
TP53 P04637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
GLA P06280 1/20 0.36
HMGCR P04035 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GPX4 P36969 1/20 0.35
PTGES O14684 1/20 0.35
ALOX5 P09917 1/20 0.35
PTGS1 P23219 1/20 0.35
STAT3 P40763 1/20 0.35
NFE2L2 Q16236 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28725225 0.77 CES2 (0.38) ALDH1A1GSK3B
SCHEMBL3658261 0.76 HSD17B10 (0.50) CYP3A4SMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL1097782 0.75 CYP3A4 (0.50) CYP3A4LMNASMN1; SMN2MEN1ALDH1A1
SCHEMBL17652108 0.75 SMN1; SMN2 (0.48) CYP3A4SMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL29531411 0.75 SMN1; SMN2 (0.48) CYP3A4SMN1; SMN2MEN1ALDH1A1KMT2A
SCHEMBL17462499 0.75 SMN1; SMN2 (0.45) MTNR1AMTNR1BSMN1; SMN2MEN1KMT2A
SCHEMBL1097516 0.74 MTNR1A (0.52) CYP3A4MTNR1AMTNR1BLMNATP53
SCHEMBL1096970 0.74 CA1 (0.54) CYP3A4MTNR1AMTNR1BLMNASMN1; SMN2
SCHEMBL31552285 0.73 HSD17B10 (0.41) CYP3A4MTNR1AMTNR1BNPSR1MEN1
SCHEMBL10620598 0.73 MEP1B (0.40) LMNASMN1; SMN2MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663255-B1 WITHANAMIDE AND WITHANOLIDE COMPOSITIONS AND METHOD OF USE THEREOF UNIV MICHIGAN STATE (US) 2014-11-12 EP disclosed
US-20080108694-A1 Novel Macrocycles and Uses Thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2008-05-08 US disclosed
US-7282593-B2 Withanamide and withanolide compositions and method of use thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2007-10-16 US disclosed
EP-1663255-A2 WITHANAMIDE AND WITHANOLIDE COMPOSITIONS AND METHOD OF USE THEREOF Michigan State University (US) 2006-06-07 EP disclosed
WO-2005061481-A1 NOVEL MA CROCYCLES AND USES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2005-07-07 WO disclosed
WO-2005034846-A2 WITHANAMIDE AND WITHANOLIDE COMPOSITIONS AND METHOD OF USE THEREOF MICHIGAN STATE UNIVERSITY (US) 2005-04-21 WO disclosed
US-20050059727-A1 Withanamide and withanolide compositions and method of use thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108694-A1 Novel Macrocycles and Uses Thereof BDKRB1, RPS4Y1, GRK4 CYP3A4 378/4885MTNR1A 1915/4885MTNR1B 2006/4885
US-20050059727-A1 Withanamide and withanolide compositions and method of use thereof ACHE, CYP51A1, HASPIN CYP3A4 469/4885MTNR1A 634/4885MTNR1B 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.